HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Anthrapyrazoles: true successors to the anthracyclines?

Abstract
The anthrapyrazoles are a new class of intercalating agents which were synthesized in order to reduce the potential for free radical generation and subsequent cardiotoxicity. Selected compounds showed a reduction in superoxide formation compared with doxorubicin plus inhibition of lipid peroxidation. Broad spectrum activity was seen against experimental tumors comparable with doxorubicin, with incomplete cross-resistance. The anthrapyrazoles bind to DNA, intercalate, preferentially inhibit DNA compared with RNA synthesis and form DNA single and double strand breaks consistent with inhibition of topoisomerase II. Clinical studies have been performed with CI-937, CI-941 and CI-942. In each case the dose-limiting toxicity was leukopenia with other toxicities being minor. CI-941 has shown significant activity in patients with advanced breast cancer and these agents appear to have a bright future.
AuthorsI R Judson
JournalAnti-cancer drugs (Anticancer Drugs) Vol. 2 Issue 3 Pg. 223-31 (Jun 1991) ISSN: 0959-4973 [Print] England
PMID1802016 (Publication Type: Journal Article, Review)
Chemical References
  • Anthracyclines
  • Antibiotics, Antineoplastic
  • anthrapyrazole
Topics
  • Animals
  • Anthracyclines
  • Antibiotics, Antineoplastic (pharmacology, therapeutic use)
  • Humans
  • Neoplasms (drug therapy)
  • Neoplasms, Experimental (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: